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Introduction: There is increasing interest in identifying a blood-
based marker for the asbestos-related tumor, malignant mesotheli-
oma. Three potential markers for mesothelioma are mesothelin,
megakaryocyte potentiating factor (MPF) and osteopontin. The pur-
pose of the current study was to directly compare these biomarkers
in the same sample population, determining their sensitivity and
specificity in establishing a diagnosis, and to determine if diagnostic
accuracy for mesothelioma is improved by combining the data from
all three markers.
Methods: Serum levels of mesothelin, MPF and osteopontin were
determined by commercially available assays in 66 samples from
patients with pleural malignant mesothelioma, 20 healthy individu-
als, 21 patients with asbestos-related lung or pleural disease, 30
patients presenting with benign pleural effusions and 30 patients
with other malignancies.
Results: Serum levels of the three markers were elevated in me-
sothelioma patients. At a level of specificity of 95% relative to
healthy controls and patients with benign asbestos related disease,
the sensitivity for mesothelioma was 34% for MPF, 47% for os-
teopontin and 73% for mesothelin. Osteopontin and MPF were
unable to differentiate patients with mesothelioma from patients
with other malignancies or those presenting with transudative pleu-
ral effusions. Combining the data from the three biomarkers using a
logistic regression model did not improve sensitivity for detecting
mesothelioma above that of the mesothelin marker alone.
Conclusion: Serum mesothelin remains the most specific marker for
the diagnosis of mesothelioma.
Key Words: Mesothelioma, Tumor markers, Mesothelin, SMRP,
MPF, Osteopontin, Diagnosis.
(J Thorac Oncol. 2008;3: 851–857)
Malignant mesothelioma is caused by exposure to asbes-tos and is a fatal disease with limited treatment op-
tions.1,2 In other forms of cancers, serum-based tumor mark-
ers have provided clinicians with a valuable aid in the
management of patients. Markers may have different roles in
diagnosis, monitoring, assessing prognosis, and in detection
of early disease. There are no markers in routine clinical use
for malignant mesothelioma, although the use of soluble
mesothelin has received recent attention.
Mesothelin is a differentiation marker of mesothelial cells.
Differential post-transcriptional and post-translational process-
ing of the mesothelin gene produces four protein products:
megakaryocyte potentiating factor (MPF),3,4 mesothelin variant
1, mesothelin variant 2,5 and serum mesothelin-related protein
(SMRP).6–8 MPF is a soluble 32 kd protein with cytokine
activity.3,4 Mesothelin is 40 kd glycosylated protein predom-
inately anchored to the cell surface of normal mesothelial cells,
but also present in solution (the physiological mechanism for
mesothelin release from the cell surface is not clear).9,10 Me-
sothelin variant 1 is the predominant form of the protein and
differs from variant 2 by only eight amino acids. SMRP is a
soluble protein with an identical N-terminal sequence to me-
sothelin but a unique C-terminal.6
Using an enzyme-linked immunosorbent assay (ELISA)
which detects both mesothelin variant 1 and SMRP, we
recently demonstrated increased levels of this biomarker in
the serum of patients with mesothelioma,11 findings recently
confirmed using the same assay12 and an independent13 assay.
Serum mesothelin is highly specific for mesothelioma (spec-
ificity 98%) with a sensitivity at diagnosis of 49% (57/117)14
and 84% in advanced disease.11 Despite very encouraging
findings showing serum mesothelin as a useful marker in
mesothelioma, we found that at diagnosis only half of me-
sothelioma patients were mesothelin positive; therefore, there
is a need for additional markers to improve diagnostic sen-
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sitivity. Possible candidate markers include proteins that are
related to mesothelin, such as MPF, or those that are inde-
pendent of mesothelin but associated with the disease such as
osteopontin.
Given the successful detection of mesothelin and SMRP
in the serum of cancer patients, two groups recently, indepen-
dently developed assays to measure levels of MPF.15,16 Onda
and colleagues showing 51/56 patients with advanced me-
sothelioma had elevated serum MPF.15 As mesothelin must
be cleaved or shed from the cell surface serum MPF may be
at least as sensitive, if not more so, than serum mesothelin as
a marker of mesothelioma. To clarify this, we measured and
compared serum mesothelin and MPF levels in the same
patient cohort using commercially available assays.
Another strategy to improve diagnostic sensitivity is to
incorporate the information from multiple markers. Patholo-
gists use suites of immunohistochemical markers in tissue to
improve diagnostic accuracy of the histopathologic find-
ings17,18 and multiple serum markers have achieved greater
sensitivity and specificity in the diagnosis of some cancers,
i.e., ovarian19,20 and prostate cancer.21
Recently, we tested the hypothesis that combining data
from two markers (mesothelin and CA125) would improve
the sensitivity of the mesothelin marker used alone to distin-
guish mesothelioma patients from other asbestos-exposed
individuals; however, we found that this combination was not
significantly different to the results for mesothelin alone.14
Osteopontin is a secreted 44 kd glycoprotein with roles
in cell-matrix interactions, cell migration, and other diverse
functions. Serum osteopontin levels are elevated in breast,
ovarian, lung, and prostrate cancer.22 Osteopontin has been
shown to be a useful adjunct to CA125 in the detection of
recurrent ovarian cancer.19 In mesothelioma serum, osteopon-
tin has a sensitivity of 78% at a specificity of 85% relative to
subjects exposed to asbestos.23
The purpose of the current study was to directly com-
pare each of these biomarkers in the same sample population
and to determine if diagnostic accuracy for mesothelioma is
improved by combining these three markers.
PATIENTS AND METHODS
Patients and Controls
Serum samples were collected from consecutive pa-
tients presenting at the respiratory clinics of either Sir Charles
Gairdner Hospital or the Hollywood Specialist Centre in
Perth, Western Australia and form part of the Australian
Mesothelioma Tissue Bank. We obtained written and oral
informed consent from participants. This study was approved
by the human ethics committees of Sir Charles Gairdner and
Hollywood Hospitals. The final diagnosis in all patients was
confirmed by pathologists experienced in the diagnosis of
mesothelioma and effusions and included clinical follow-up
of all cases until death or for an average of 6.8 months (range,
1–42 months) to confirm that the clinical pattern matched the
diagnosis. Effusions were classified as being malignant or
nonmalignant on the basis of cytologic and immunohisto-
chemical features. Nonmalignant effusions were classified as
exudates or transudates by Light’s criteria.24
Blood samples were collected by routine venepuncture
into clotted blood tubes. Samples were allowed to clot for at
least 2 hours at room temperature, or alternatively were
stored at 4°C before processing. Samples were centrifuged at
1200 rpm for 10 minutes, then the supernatant was removed,
aliquoted, and stored at 80°C until use.
Serum Mesothelin
Soluble mesothelin concentrations were determined in
duplicate following the manufacturer’s instructions using a dou-
ble-determinant ELISA assay, the MESOMARK kit, supplied
by Fujirebio Diagnostics (Malvern, PA). Mesothelin concentra-
tions were determined from a standard curve performed on each
plate and expressed as nanomolar. Dilution of samples was
carried out, if necessary, using the diluent supplied by the
manufacturer. All assays were performed on coded samples
by technical staff unaware of the patient’s diagnosis.
MPF Assay
The Human N-ERC/Mesothelin Assay kit was pur-
chased from Immuno-Biologic Laboratories (Gunma, Japan)
and the manufacturer’s recommended protocol was followed.
Serum samples were assayed undiluted and concentrations of
MPF were determined from a standard curve performed in
parallel. The manufacturer’s reported assay sensitivity was
0.024 ng/ml; the concentrations for samples from 0.024 ng/ml
to 0.011 ng/ml were extrapolated from the standard curve, for
the purposes of data analysis concentrations of samples below
0.011 ng/ml were assigned a value of 0.005 ng/ml.
Osteopontin Assay
The human osteopontin assay, a double-determinant
ELISA, was purchased from Immuno-Biologic Laboratories.
The manufacturer’s recommended protocol was followed
except serum was used as the assay substrate instead of
plasma. Serum samples were diluted 1:3 in buffer supplied
with the kit. The manufacturer’s reported assay sensitivity
was 3.33 ng/ml, the concentrations for samples from 3.3
ng/ml to 0.5 ng/ml were extrapolated from the standard curve,
and for the purposes of data analysis concentrations of sam-
ples below 0.5 ng/ml were assigned a value of 0.1 ng/ml.
Statistical Analysis
Differences between groups of patients were assessed
by Student t test after transforming the biomarker values to
the log scale for which the distributions were closer to
normality. For the same reason, median biomarker values
were estimated from the mean on the log scale and exponen-
tiated to provide the estimate of the median on the original
scale. All reported p values are two sided. A level of p 0.05
was accepted as significant. Receiver operating characteristic
(ROC) curves display the trade-off between sensitivity and
specificity for biomarkers differentiating between groups of
patients. Area under the curve (AUC) for two biomarkers,
including “markers” formed by combining multiple biomar-
kers, was compared using the method of DeLong et al.,25
which accounts for the correlation because of the markers
being measured on the same set of serum samples. To
combine biomarkers, we first transformed data with the
natural logarithm, and then standardized the markers relative
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to asbestos-exposed controls. Logistic regression to predict
case/control status was used to determine the weight given
each marker. Markers were multiplied by their logistic re-
gression coefficient and added to give a combined marker
value. Pearson’s correlation coefficient was used to assess
correlations between different biomarkers (log scale).
RESULTS
Patient Characteristics
Serum samples were collected from 66 patients with
pleural malignant mesothelioma; 9 with predominantly sar-
comatoid histology and 57 with predominantly epithelioid
histology or from whom a diagnosis was made on immuno-
cytological grounds.26 Sera were collected from 20 appar-
ently healthy individuals, 10 of whom had no reported pre-
vious asbestos exposure, and 10 with exposure. Samples were
also collected from 21 patients with benign asbestos-related
pulmonary disease (asbestosis and/or pleural plaques); from
30 patients with nonmalignant effusions (10 had exudative
effusions, 10 had effusions relating to an infection, and 10
had transudate effusions); from 20 people who presented with
effusions because of other malignancies (10 with primary
lung cancer, 3 with breast cancer, 2 each with colon and
pancreatic cancer, and one each with melanoma, sarcoma,
and non-Hodgkin lymphoma) and from 10 additional cases of
lung cancer who did not present with an effusion (Table 1).
MPF Levels in Serum
Serum MPF levels in patients with mesothelioma
ranged from undetectable to 5.9 ng/ml (Figure 1). Levels
ranged from undetectable to 0.7 ng/ml in patients with me-
sothelioma tumors of sarcomatoid histology, levels which
were lower than those observed in patients with epithelial-
type mesotheliomas although not significantly so (p  0.09).
Serum MPF levels were significantly higher in the serum of
patients with mesothelioma than the healthy control popula-
tion (p  0.007), the patients with benign asbestos-related
disease (p 0.01), and patients with nonmalignant exudative
effusions (p  0.01). There was no difference in MPF levels
between those patients with mesothelioma, lung cancer, or
with effusions of a transudate or malignant nature.
Osteopontin Levels in Serum
Serum osteopontin levels in patients with mesotheli-
oma ranged from undetectable to 438 ng/ml (Figure 1). There
was no relationship between the levels of osteopontin and the
histologic diagnosis of the patients’ mesothelioma (Table 1).
Serum osteopontin levels were significantly higher in the
serum of patients with mesothelioma than the healthy control
population (p  0.0002), the patients with benign asbestos-
related disease (p  0.0001), and the patients with nonma-
lignant exudative effusions (p  0.0002). There was no
difference in osteopontin levels between patients with me-
sothelioma, lung cancer, or effusions of a transudate or
malignant nature. There was no significant difference in
serum osteopontin levels between healthy control individuals
and individuals with benign asbestos-related disease.
Mesothelin Levels in Serum
Serum mesothelin levels were significantly higher in
patients with mesothelioma compared with healthy controls
(p  0.0001), individuals with benign asbestos-related dis-
ease (p  0.0001), patients with benign effusions (p 
0.005), patients with malignant effusions (p  0.0006), and
patients with lung cancer (p 0.03). Serum mesothelin levels
TABLE 1. Patient Characteristics and Biomarker Levels
No. of
Cases
Median Age,
yr (range) Osteopontina,b
No. of Positive
Samplesc MPFa,b,d
No. of Positive
Samplesc Mesothelina,c
No. of Positive
Samplesc
MM—all 66 (5F) 69 (50–84) 14.8  8.2 30/66 0.19  13.5 21/66 4.7  3.4 48/66
Epithelial and
cytology
57 (5F) 70 (50–84) 15.9  8 26/57 0.23  13.4 21/57 5.7  3.3 47/57
Sarcomatoid 9 (0F) 68 (53–77) 9.2  10.4 4/9 0.05  10.5 0/9 1.3  1.3 1/9
Healthy controls—all 20 (7F) 55 (33–64) 2  7.3** 0/20 0.05  5.8* 1/20 0.4  3.4*** 0/20
Nonasbestos exposed 10 (2F) 48 (33–58) 1.2  10.5 0/10 0.04  8.4 1/10 0.24  5.1 0/10
Asbestos exposed 10 (5F) 58 (40–64) 3.2  4.6 0/10 0.05  4.1 0/10 0.65  1.32 0/10
Benign controls—all 21 (4F) 71 (49–86) 1.8  8** 3/20 0.09  6.2 (NS) 1/20 0.87  2.4*** 1/20
Asbestosis 11 (3F) 70 (49–86) 1.8  8.6 1/10 0.06  6.6 0/10 0.76  3.1 1/10
Asbestosis and plaques 10 (1F) 73 (60–86) 1.9  8.5 2/10 0.14  5.5 1/10 1.0  1.6 0/10
Pleural effusions
Transudate 9 (2F) 76 (48–82) 15.6  11 (NS) 5/10 0.2  8.9 (NS) 1/10 1.7  1.9* 5/10
Exudate 10 (1F) 76 (32–80) 1.8  12.1* 0/10 0.05  8.3 (NS) 0/10 0.8  1.8*** 0/10
Exudate—infection 9 (5F) 64 (50–86) 1.7  9** 1/10 0.08  6.1 (NS) 0/10 0.7  3*** 2/10
Malignancy 20 (10F) 74 (50–83) 20.7  8.1 (NS) 10/20 0.33  4.6 (NS) 0/20 1.6  2.5* 9/20
Lung cancer 10 (2F) 74 (58–82) 19  7.5 (NS) 7/10 0.36  3.6 (NS) 2/10 1.79  2.95* 5/10
a Expontiated mean of log transformed data  standard error.
b Significant difference between indicated cohorts and the mesothelioma cohort as a whole (n  66) as determined by Student t test (NS is not significant; *p  0.05; **p 
0.001; ***p  0.0001).
c The number of samples above the 95% specificity level as determined for each marker and described in Table 2 below.
d MPF concentrations determined from Human N-ERC/Mesothelin Assay (IBL).
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were significantly higher in patients with mesothelioma tu-
mors of epithelial-like histology than those with predomi-
nately sarcomatoid histology (p  0.0004) (Table 1).
Comparison of Multiple Biomarker Levels
When ROC curves were generated to assess the ability
of the markers to distinguish patients with mesothelioma
from the healthy controls and the patients with benign asbes-
tos-related disease, the AUC for MPF was 0.614 (95%
confidence interval [CI], 0.508–0.721), for osteopontin it
was 0.757 (95% CI, 0.666–0.848) and for mesothelin it was
0.915 (95% CI, 0.869–0.968) (Figure 2). The AUC for
mesothelin was significantly higher than for MPF or for
osteopontin. From the curves, the sensitivities were deter-
mined for specificities of 85%, 90%, 95%, and 98% (Table
2). In the present study, at a specificity of 95%, the MPF
assay had a sensitivity of 34%; the osteopontin assay had a
sensitivity of 47%, and the mesothelin assay had a sensitivity
of 73%.
A bivariate scattergram of mesothelin versus MPF
(Figure 3A) and osteopontin (Figure 3B) levels in individuals
with mesothelioma and controls with the threshold values for
95% specificity indicated only one individual who had ele-
vated MPF and osteopontin levels who was negative for
mesothelin, and another individual with sarcomatoid variant
with elevated osteopontin but negative mesothelin, demon-
strating that neither MPF nor osteopontin add significant
information about the presence of mesothelioma to mesothe-
FIGURE 2. ROC curve showing accuracy of serum biomarker
concentration in differentiating all patients with mesothelioma
(n  66) from healthy and benign controls (n  41).
FIGURE 1. Biomarker concentrations in serum. Biomarker
concentrations were determined at least in duplicate by
ELISA and individual patient values are plotted on the graph.
A, MPF; B, osteopontin; and C, mesothelin.
TABLE 2. Sensitivity of Individual Biomarkers Estimated at
Different Levels of Specificity for Differentiating all Patients
with Mesothelioma (n  66) from Healthy and Benign
Controls (n  41)
Estimated Sensitivities
85%
Specificity
(threshold
value)
90%
Specificity
(threshold
value)
95%
Specificity
(threshold
value)
98%
Specificity
(threshold
value)
MPF 39 (0.6) 36 (0.7) 34 (1) 34 (1.3)
Osteopontin 55 (10.5) 53 (12) 47 (18) 22 (77)
Mesothelin 81 (1.25) 78 (1.4) 73 (1.6) 68 (1.8)
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lin. There was a group of approximately 40% and 34%
mesothelioma patients positive for mesothelin and negative
for MPF and osteopontin, respectively. Examining only the
patients with mesothelioma, there was a significant correla-
tion between mesothelin levels and MPF (r  0.477; p 
0.01) and osteopontin (r  0.373; p  0.01) levels.
A bivariate scattergram of MPF and osteopontin re-
vealed that the majority of patients with elevated osteopontin
had elevated MPF which was reflected in a correlation of r 
0.632 (p  0.01) between these markers (Figure 3C).
The results of using a logistic regression model to
combine the data from the three markers are presented in
Figure 4 and Table 3. Those combinations that include
mesothelin all increase the AUC value compared with the
panel without mesothelin; however, neither MPF nor os-
teopontin significantly increased the AUC when added to a
panel. All combined markers with mesothelin had AUCs in
the range 90.7 to 91.5% which was not significantly different
from the AUC for mesothelin alone, whereas the AUC for the
combined marker formed from MPF and osteopontin had an
AUC of 74.5% which was significantly lower than any AUC
from a combined marker with mesothelin at p  0.001.
DISCUSSION
The development of multiple markers in disease diag-
nostics is the goal of a number of biomarker research centers.
This study shows no improvement in combining serum os-
teopontin and MPF with mesothelin in determining the accu-
racy of diagnosis of malignant mesothelioma over the me-
sothelin marker used alone.
MPF levels are reported to be elevated in mesothelioma
patients.15,16 Using a commercial version of the assay devel-
oped by Shiomi et al., we found that, at a specificity of 95%,
34% of mesothelioma patients had elevated levels of MPF,
less than the 7/716 and 51/56 positive mesothelioma patients
previously reported.15 Such a difference may reflect differ-
ences in the stage distribution of the mesothelioma patients as
Onda et al.15 reported that all their subjects had advanced
disease. A diagnostic test with high sensitivity only in patients
who have advanced cancer is clearly of little clinical value.
One might expect that the MPF and mesothelin assays
would have similar sensitivity and specificity. Our finding
that this was not the case was contrary to the notion that MPF
would be a more sensitive marker for mesothelioma than
mesothelin because of the latter’s need to be cleaved or shed
from the cell surface. For the same specificity, fewer me-
sothelioma patients had elevated MPF compared with the
numbers with elevated mesothelin. The reason for the differ-
ence in sensitivity of the two markers of the same precursor
protein may simply be a reflection of the relative stabilities of
the molecules, though the physiology of their relative stabil-
ities in vivo and clearance kinetics is yet to be defined.
Osteopontin is a secreted glycol-phosphoprotein which
is produced by many cell types including osteoclasts, osteo-
blasts, epithelial cells of the breast, kidney and skin, nerve
FIGURE 3. Bivariate scattergram of biomarker concentra-
tions determined in serum from individual patients with me-
sothelioma () and from healthy and benign controls (‚).
Dashed lines represent the level at which the individual bi-
omarker has a specificity of 95%. A, MPF concentrations
plotted against mesothelin; B, osteopontin against mesothe-
lin; and C, osteopontin against MPF.
FIGURE 4. ROC curve showing accuracy of serum biomarker
concentrations individually and combined using a logistic re-
gression model in differentiating all patients with mesothelioma
(n  66) from healthy and benign controls (n  41).
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cells, endothelial cells, and immune cells such as T cells,
natural killer cells, and macrophages. In malignancy, os-
teopontin is believed to play a role in tumor progression,
growth, invasiveness, and metastasis. It has been shown to be
elevated in the serum of patients with melanoma, breast, lung,
colorectal, stomach, and ovarian cancer22,27 and recently also
in mesothelioma.23,28 The results of our current study confirm
that serum levels of osteopontin are elevated in some me-
sothelioma patients. One concern that remains is the nature of
the test sample. In the three mesothelioma-osteopontin stud-
ies to date where osteopontin was measured in the serum, the
protein may potentially be cleaved by thrombin also present
in the sera and results may not reflect the true levels of the
protein in the blood. Grigoriu et al. reported that although
osteopontin levels were higher in plasma, the ability of
osteopontin to discriminate between patients with mesotheli-
oma and healthy asbestos-exposed subjects was similar when
using plasma or serum levels.28 We restricted the current
study to serum as we needed to use the same sample for all
patients. The need to use plasma, serum, or other collection
methods needs further study.
Although serum levels of osteopontin discriminate be-
tween mesothelioma patients and healthy controls,23,28 levels
of osteopontin alone are unlikely to be of clinical value in
mesothelioma diagnosis. Furthermore, serum osteopontin levels
are elevated in other malignancies, as described above. In
addition, some common nonmalignant, nonpleural effusion-
associated conditions including coronary artery disease, in-
terstitial pneumonia, and other benign pulmonary disease28–30
can result in increased levels of osteopontin in the serum.
We have previously found that individual patients with
mesothelioma exhibit different biomarker profiles: either both
CA125 and mesothelin, only one or neither marker. This was
not found to be the case with the pattern of expression of
osteopontin and mesothelin as virtually all osteopontin posi-
tive mesothelioma patients were positive for mesothelin. This
high degree of concordance means that combining such markers
would be unlikely to add to sensitivity. As the various combi-
nations of markers discriminated betweenmesothelioma patients
and controls, no better than when mesothelin was used alone,
our current practice is to measure serum mesothelin as the
preferred biomarker for suspected mesothelioma and not include
assays for the other biomarkers.
The mesothelin biomarker represents the best available
serum biomarker for mesothelioma. An elevated mesothelin
level is highly suggestive of malignancy, and particularly of
mesothelioma. Other markers are needed to improve the
sensitivity for mesothelioma in symptomatic patients, and
possibly for use in any screening strategy for asbestos-
exposed individuals. Studies are therefore ongoing to identify
new mesothelioma-specific markers.
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